Form 4: Assembly Biosciences CSO Receives RSU Grant

Chief Scientific Officer William E. Delaney IV acquired 14,000 restricted stock units following stockholder approval of the company's equity incentive plan.

Summary

• William E. Delaney IV, Chief Scientific Officer of Assembly Biosciences, Inc., was granted 14,000 restricted stock units (RSUs).
• The grant was contingent upon the June 4, 2026, stockholder approval of an amendment to the 2018 Stock Incentive Plan.
• The RSUs vest in four equal annual installments starting March 29, 2027, through March 29, 2030.
• The reporting person also acquired 688 shares via the Employee Stock Purchase Plan on May 14, 2026.
• Total beneficial ownership following these transactions is 60,330 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding executive compensation that does not signal a change in company fundamentals.

Positives

• Alignment of executive interests with long-term shareholder value through multi-year RSU vesting schedule.
• Successful stockholder approval of the Plan Amendment indicates support for the company's equity compensation strategy.

Negatives

• The grant represents potential future dilution to existing shareholders, though standard for executive compensation.

Risks

• Vesting is contingent upon continuous service, creating potential retention risk if the executive departs before 2030.

Future Outlook

The RSUs are scheduled to vest in four equal installments on March 29 of 2027, 2028, 2029, and 2030, contingent upon the executive's continuous service.

Industry Context

StockSavvy.ai notes that equity-based compensation remains the standard for retaining high-level scientific talent in the competitive biotechnology sector, particularly following successful plan amendments.

Comparison to Industry Standards

• The use of four-year vesting schedules for executive RSUs is consistent with standard corporate governance practices in the U.S. biotech industry.
• The reliance on stockholder approval for plan amendments aligns with institutional investor expectations for transparency in equity dilution.

Corporate Governance

Stakeholder Impact

• Shareholders: Minor dilution impact from the issuance of new shares under the incentive plan.

Next Steps

• Vesting of the first tranche of RSUs on March 29, 2027.

Key Dates

Keywords

ASMB, Assembly Biosciences, Form 4, Insider Trading, Executive Compensation, Biotech